Armed CAR-T cell therapy

Fighting cancer with armed CAR-T

Armed Cell Therapeutics develops multi-targeting armed CAR-T cells, built to stay fit, persist and function inside the tumor.

Designed for deeper and more durable responses.

Our science View pipeline →
2LEAD PROGRAMS
5PROGRAMS IN DISCOVERY
Our mission

For patients with hard-to-treat cancers

We develop innovative armed CAR-T therapies, with the aim of reaching every cancer patient who needs them. Our first programs focus on non-Hodgkin lymphoma and small cell lung cancer.

Our strategy

Four principles behind every program

01Multi-targeting versus mono-targeting
02Improving T-cell fitness, persistence & function
03Focused on highest unmet need
04Accelerating development
Our science

What makes an armed CAR-T cell

01 / T CELL
T cell

T CELL

The patient's own immune cell, collected and expanded to become the foundation of the therapy.

02 / CAR
Chimeric antigen receptor on the T cell membrane

CAR

A chimeric antigen receptor that lets the T cell recognize and bind tumor cells directly.

03 / ARMED
Armed CAR-T cell with payload shield

ARMED

Additional payloads designed to protect the CAR-T cell from exhaustion and help it keep working in a hostile microenvironment.

Pipeline

The two lead programs focusing on non-Hodgkin lymphoma and small cell lung cancer

Both lead programs are preparing for first-in-human (FIH) studies. FIH has not yet started.

PROGRAMDISCOVERYPRECLINICALFIHPHASE 1
Lead 1 · biCAR-T, armedHemato-oncology · non-Hodgkin lymphoma
LEAD 1
Lead 2 · CAR-T, armedSolid tumor · SCLC
LEAD 2
Confidential · multi-targeting armed CAR-T
Confidential · multi-targeting armed CAR-T
Confidential · multi-targeting armed CAR-T
CompletedIn progressPreparing for FIH

Targets not disclosed.

About us

Translating armed CAR-T science into clinical programs

Armed Cell Therapeutics brings together cell-therapy scientists, clinicians and company builders with long experience in cell therapy, many of whom have worked together before.

Meet the team →
Team

An experienced team that has worked together before

Experience across discovery, development, CMC and company building.

Board of Directors
Paul Stoffels, MD Chair of the Board FOUNDER
Peter Verhaeghe Board Member & Counsel FOUNDER
John Mellors, MD Executive Board Member & CSO FOUNDER
Leadership team
Willemijn Kremer Chief Executive Officer FOUNDER
John Mellors, MD Chief Scientific OfficerFOUNDER
Emmanuel Casier Emmanuel Casier Chief Legal OfficerFOUNDER
Weizao Chen, PhD Head of DiscoveryCO-FOUNDER
Zhi-Chun Ding, PhD Head of Cell EngineeringCO-FOUNDER
Yufei Xiang, MD Head of Early DevelopmentCO-FOUNDER
Cindy Adams, MS Head of Preclinical EvaluationCO-FOUNDER
Natalie Dean Head of OperationsCO-FOUNDER
Bas Bremer Bas Bremer Head of Finance
Cristy Dougherty Cristy Dougherty Head of CMC (consultant)CO-FOUNDER

Behind them stands a wider team of scientists, engineers and professionals whose expertise carries our programs forward every day.

Contact

Partner with us

We welcome conversations with investors, clinical collaborators and manufacturing partners.

Barricadenplein 13, 1000 Brussels, Belgium 1401 Forbes Avenue, Suite 350, Pittsburgh, PA 15219, USA Get in touch
News

Newsroom

Armed Cell Therapeutics Acquires Armed CAR-T Portfolio from Lakefront, with Lead Programs in Non-Hodgkin Lymphoma and Small Cell Lung Cancer

Read the press release (PDF) →

For press and media enquiries, please contact media@armedcelltx.com